Familial risk of myeloid malignancies

Print Friendly, PDF & Email


Three generations of
women in a family
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The study showed that first-degree relatives of patients with myeloid malignancies had double the risk of developing a myeloid malignancy themselves, when compared to the general population. The researchers... [Read Article]
Print Friendly, PDF & Email

Study could change treatment of MLSM7

Print Friendly, PDF & Email


Study authors Tamara
Lamprecht, Jason Schwartz,
Jing Ma, and Jeffrey Klco
Photo from St. Jude
Children’s Research
Hospital/Justin Veneman
New findings could help improve treatment of an inherited bone marrow disorder known as myelodysplasia and leukemia syndrome with monosomy 7 (MLSM7), according to researchers. While studying families affected by MLSM7, researchers identified germline mutations... [Read Article]
Print Friendly, PDF & Email

Treatments, disease affect spermatogonia in boys

Print Friendly, PDF & Email


Male germinal epithelium
showing spermatogonia,
spermatocytes, spermatids,
and spermatozoa
Image from Dreamstime
Alkylating agents, hydroxyurea (HU), and certain non-malignant diseases can significantly deplete spermatogonial cell counts in young boys, according to research published in Human Reproduction. Boys who received alkylating agents to treat cancer had significantly lower spermatogonial cell counts than control subjects or boys... [Read Article]
Print Friendly, PDF & Email

A new use for ibrutinib?

Print Friendly, PDF & Email


Neutrophil engulfing bacteria
Image by Volker Brinkmann
Preclinical research suggests ibrutinib could treat G-CSFR-mutant myeloid disorders. “Mutations in G-CSFR have a harmful effect on the production of neutrophils and are reported in patients with several blood disorders, including severe congenital neutropenia, chronic neutrophilic leukemia, and acute myeloid leukemia,” said Ken Greis, PhD, of the University... [Read Article]
Print Friendly, PDF & Email

FDA lifts hold on trial of MYC inhibitor

Print Friendly, PDF & Email


Micrograph showing MDS
The US Food and Drug Administration (FDA) has lifted the clinical hold on a phase 1b trial of APTO-253. APTO-253 is a small molecule that inhibits expression of the c-Myc oncogene without causing general myelosuppression of the bone marrow, according to Aptose Biosciences Inc., the company developing the drug. Aptose was testing... [Read Article]
Print Friendly, PDF & Email

Art education benefits blood cancer patients

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of CDC
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant. The BVAI involved an educator teaching patients art technique one-on-one for approximately 30 minutes. After a single session, patients had significant improvements in... [Read Article]
Print Friendly, PDF & Email

Drug shows promise for treating AML, MDS

Print Friendly, PDF & Email


Lab mouse
Preclinical results support clinical testing of an experimental agent in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to researchers. The agent, ALRN-6924, was shown to combat AML and MDS by restoring activity of the tumor-suppressing protein p53. ALRN-6924 exhibited antileukemic activity in AML cells and mouse models of the disease, as... [Read Article]
Print Friendly, PDF & Email

Gene variants linked to survival after HSCT

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research has revealed a link between rare gene variants and survival after hematopoietic stem cell transplant (HSCT). Researchers performed exome sequencing in nearly 2500 HSCT recipients and their matched, unrelated donors. The sequencing revealed several gene variants—in both donors and recipients—that were significantly associated with overall survival... [Read Article]
Print Friendly, PDF & Email

Agent exhibits activity in leukemias, MDS

Print Friendly, PDF & Email


AML cells
The experimental agent prexigebersen (formerly BP1001) was considered well-tolerated and demonstrated early evidence of activity against relapsed/refractory hematologic disorders in a phase 1/1b trial. The drug reduced blasts in the bone marrow and peripheral blood for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). When given... [Read Article]
Print Friendly, PDF & Email

Manufactured graft deemed safe in blood cancer patients

Print Friendly, PDF & Email


Peripheral blood
stem cell graft
Phase 1 results suggest a programmed cellular therapy is safe for use in patients with hematologic malignancies. The therapy, ProTmune, is being developed as a next-generation allogeneic graft intended to reduce the incidence and severity of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT). Three of 7... [Read Article]
Print Friendly, PDF & Email

Expanded UCB product can stand alone

Print Friendly, PDF & Email


Mitchell Horwitz, MD
The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the 2018 BMT Tandem Meetings. Researchers found that a single NiCord unit provided “robust” engraftment in a phase 1/2 study of patients with high-risk hematologic malignancies. NiCord recipients had quicker... [Read Article]
Print Friendly, PDF & Email